Mekinist and Fluid retention - a phase IV clinical study of FDA data

Summary:

Fluid retention is reported as a side effect among people who take Mekinist (trametinib dimethyl sulfoxide), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Tafinlar, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Fluid retention when taking Mekinist. It is created by eHealthMe based on reports of 17,345 people who have side effects when taking Mekinist from the FDA, and is updated regularly.

What is Mekinist?

Mekinist has active ingredients of trametinib dimethyl sulfoxide. eHealthMe is studying from 17,350 Mekinist users. Check the latest studies of Mekinist.

What is Fluid retention?

Fluid retention (an abnormal accumulation of fluid in the blood) is found to be associated with 1,697 drugs and 2,451 conditions by eHealthMe. Check the latest studies of Fluid retention.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 14, 2026

17,345 people reported to have side effects when taking Mekinist.
Among them, 25 people (0.14%) have Fluid retention.

Among these 25 people:

How long have people been on Mekinist when they have Fluid retention? *

What is the gender of people who have Fluid retention when taking Mekinist? *

female: 60 %
male: 40 %

What is the age of people who have Fluid retention when taking Mekinist? *

What are other drugs people take besides Mekinist? *

What are other side effects people have besides Fluid retention? *

Fever: 7 people, 28.00%
Fatigue (feeling of tiredness): 6 people, 24.00%
Rashes (redness): 6 people, 24.00%
Hypotension (abnormally low blood pressure): 6 people, 24.00%
Chills (felling of cold): 5 people, 20.00%
Peripheral Swelling: 5 people, 20.00%
Drug Intolerance (drug sensitivity): 4 people, 16.00%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 3 people, 12.00%
Haemoglobin Decreased: 3 people, 12.00%
Headache (pain in head): 3 people, 12.00%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 5 people, 20.00%
Ovarian Cancer (cancer of ovary): 4 people, 16.00%
Thyroid Cancer: 2 people, 8.00%
Malignant Melanoma (skin cancer rises from melancytes): 2 people, 8.00%
Tumor: 1 person, 4.00%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 1 person, 4.00%
Joint Pain: 1 person, 4.00%
Astrocytoma (tumour of the brain that originate in a particular kind of glial-cells): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mekinist and have Fluid retention?

- Check whether Fluid retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mekinist:

Mekinist (17,350 reports)

Fluid retention treatments and more:

Fluid retention (79,661 reports)

Browse all side effects of Mekinist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fluid retention:

Fluid retention (1,697 drugs)

Browse all the conditions that are associated with Fluid retention:

Fluid retention (2,451 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on trametinib dimethyl sulfoxide (the active ingredients of Mekinist) and Mekinist (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.